Amir Pelleg
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Amir Pelleg has a total of 11 co-authors. Here are the top co-authors by number of shared publications:
- Peter John Barnes
National Heart and Lung Institute, Imperial College, London SW3 6LY, United Kingdom
3 shared publications Daniel Flammang
Syncope Management Center, University Hospital La Croix Rousse, Lyon, France; 2Cardiovascular Division, Department of Medicine, University of Minnesota, Minneapolis, MN; and 3Department of Medicine, Drexel University College of Medicine, Philadelphia, PA
2 shared publicationsOzen K. Basoglu
Department of Chest Diseases, Ege University Faculty of Medicine, Izmir, Turkey
2 shared publicationsSergei A. Kharitonov
Airway Disease Section, National Heart and Lung Institute, Imperial College, London, UK
2 shared publicationsBernard Belhassen
1 shared publicationDavid Benditt
University of Minnesota Medical School
1 shared publication
Latest Publications
- Open Access
- 1 August 2017
- Published by Elsevier in Pulmonary Pharmacology & Therapeutics
- Vol. 45, 13-18
Contrasting effects of ATP and adenosine on capsaicin challenge in asthmatic patients
- 1 August 2017
- Published by Elsevier in Pulmonary Pharmacology & Therapeutics
- Vol. 45, 13-18
Open AccessContrasting effects of ATP and adenosine on capsaicin challenge in asthmatic patients
- 1 November 2016
- Published by Wolters Kluwer Health in American Journal of Therapeutics
- Vol. 23 (6) , e1347-e1352
Adenosine 5′-Triphosphate Test in the Management of Patients With Syncope
The response to adenosine 5′-triphosphate (ATP) identifies patients with syncope who might benefit from pacemaker therapy (ATP test). Two measures have been used to determine the outcome of the ATP test, which have lead to contrasting conclusions regarding its utility: (1) the duration of cardiac pause (CP) mainly due to AV block and (2) the longest RR interval (RRmax). We tested the hypothesis that the discrepancy regarding the utility of the ATP test is mainly because of the different way the 2 measures determine the outcome of the test. Post hoc analysis was applied to data obtained from patients with syncope (n = 33) with a positive and negative ATP test based on the CP duration and RRmax, respectively, subjected to pacemaker therapy. In 19 and 14 patients, the pacemaker was programmed to function as AAI pacing at 30 ppm (control) and as DDD pacing at 70 ppm, respectively. During the follow-up period of 17.0 ± 8.6 months, syncope recurred in only 1 of the 14 patients with DDD pacing; in contrast, 10 of 19 patients with AAI30 pacing experienced syncope within the first 5.3 ± 5.2 months of follow-up (P< 0.009; recurrence rate). The ATP test, the outcome of which is determined by the CP measure, is a useful diagnostic test for the identification of patients with bradycardic syncope who may benefit from pacemaker therapy; the identification of such patients would be missed when the RRmaxmeasure is used to determine the outcome of the test. The efficacy of DDD pacing suggests that atrioventricular nodal conduction block is the primary cause of syncope in patients with a positive ATP test based on the CP measure.
- 1 November 2016
- Published by Wolters Kluwer Health in American Journal of Therapeutics
- Vol. 23 (6) , e1347-e1352
Adenosine 5′-Triphosphate Test in the Management of Patients With Syncope
The response to adenosine 5′-triphosphate (ATP) identifies patients with syncope who might benefit from pacemaker therapy (ATP test). Two measures have been used to determine the outcome of the ATP test, which have lead to contrasting conclusions regarding its utility: (1) the duration of cardiac pause (CP) mainly due to AV block and (2) the longest RR interval (RRmax). We tested the hypothesis that the discrepancy regarding the utility of the ATP test is mainly because of the different way the 2 measures determine the outcome of the test. Post hoc analysis was applied to data obtained from patients with syncope (n = 33) with a positive and negative ATP test based on the CP duration and RRmax, respectively, subjected to pacemaker therapy. In 19 and 14 patients, the pacemaker was programmed to function as AAI pacing at 30 ppm (control) and as DDD pacing at 70 ppm, respectively. During the follow-up period of 17.0 ± 8.6 months, syncope recurred in only 1 of the 14 patients with DDD pacing; in contrast, 10 of 19 patients with AAI30 pacing experienced syncope within the first 5.3 ± 5.2 months of follow-up (P< 0.009; recurrence rate). The ATP test, the outcome of which is determined by the CP measure, is a useful diagnostic test for the identification of patients with bradycardic syncope who may benefit from pacemaker therapy; the identification of such patients would be missed when the RRmaxmeasure is used to determine the outcome of the test. The efficacy of DDD pacing suggests that atrioventricular nodal conduction block is the primary cause of syncope in patients with a positive ATP test based on the CP measure.
- 6 November 2011
- Published by Springer Nature in Purinergic Signalling
- Vol. 8 (S1) , 57-60
ATPace™: injectable adenosine 5′-triphosphate
- 6 November 2011
- Published by Springer Nature in Purinergic Signalling
- Vol. 8 (S1) , 57-60
ATPace™: injectable adenosine 5′-triphosphate
- 1 July 2010
- Published by Wolters Kluwer Health in Journal of Cardiovascular Pharmacology
- Vol. 56 (1) , 106-109
The Mechanism of the Negative Chronotropic and Dromotropic Actions of Adenosine 5'-triphosphate in the Heart: An Update
Adenosine 5'-triphosphate (ATP) plays a critical role in intracellular metabolism and energetics. Extracellular ATP is rapidly degraded to adenosine by ectoenzymes. Both ATP and adenosine suppress cardiac pacemakers' automaticity and atrioventricular nodal conduction, albeit via the different mechanism of actions. This historical update summarizes the current knowledge regarding the negative chronotropic and dromotropic actions of ATP and discusses the clinical implications regarding the utility of ATP as a diagnostic and therapeutic agent in the management of neutrally mediated syncope and paroxysmal supra ventricular tachycardia.
- 1 July 2010
- Published by Wolters Kluwer Health in Journal of Cardiovascular Pharmacology
- Vol. 56 (1) , 106-109
The Mechanism of the Negative Chronotropic and Dromotropic Actions of Adenosine 5'-triphosphate in the Heart: An Update
Adenosine 5'-triphosphate (ATP) plays a critical role in intracellular metabolism and energetics. Extracellular ATP is rapidly degraded to adenosine by ectoenzymes. Both ATP and adenosine suppress cardiac pacemakers' automaticity and atrioventricular nodal conduction, albeit via the different mechanism of actions. This historical update summarizes the current knowledge regarding the negative chronotropic and dromotropic actions of ATP and discusses the clinical implications regarding the utility of ATP as a diagnostic and therapeutic agent in the management of neutrally mediated syncope and paroxysmal supra ventricular tachycardia.
- Open Access
- 20 June 2008
- Published by Springer Nature in Purinergic Signalling
- Vol. 4 (4) , 407-408
The first second-generation adenosine drug enters the US market
- 20 June 2008
- Published by Springer Nature in Purinergic Signalling
- Vol. 4 (4) , 407-408
Open AccessThe first second-generation adenosine drug enters the US market